MiR-133a acts as an anti-oncogene in Hepatocellular carcinoma by inhibiting FOSL2 through TGF-β/Smad3 signaling pathway
- 1 November 2018
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 107, 168-176
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Decreased expression of miR-133a correlates with poor prognosis in colorectal cancer patientsWorld Journal of Gastroenterology, 2014
- Association Study of FOS-Like Antigen-2 Promoter Polymorphisms With Papillary Thyroid Cancer in Korean PopulationClinical and Experimental Otorhinolaryngology, 2014
- Direct Effects of Hepatitis B Virus-Encoded Proteins and Chronic Infection in Liver Cancer DevelopmentDigestive Diseases, 2013
- MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cellsCancer Genetics, 2012
- Fra-2/AP-1 controls bone formation by regulating osteoblast differentiation and collagen productionJournal of Cell Biology, 2010
- Fra-2 mediates oxygen-sensitive induction of transforming growth factor β in cardiac fibroblastsCardiovascular Research, 2010
- Spatial analysis of hepatocellular carcinoma and socioeconomic status in China from a Population-based Cancer RegistryCancer Epidemiology, 2010
- The transcription factor Fra‐2 regulates the production of extracellular matrix in systemic sclerosisArthritis & Rheumatism, 2009
- AP-1: a double-edged sword in tumorigenesisNature Reviews Cancer, 2003
- AP-1 as a regulator of cell life and deathNature Cell Biology, 2002